Priti Krishtel

Building a bigger table for a more equitable drug development system

  • February 22, 2021

On December 7, 2020, the Kaiser Permanente Institute for Health Policy hosted the first of a 2-part virtual forum examining racial equity in the drug development system, including during initial investments and research, patent and regulatory processes, supplier and physician…

Biosimilars at Kaiser Permanente

  • December 16, 2020

Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic…

The Medicaid Drug Rebate Program and the impact of “best price” rules

  • October 19, 2020

The Medicaid Drug Rebate Program (MDRP) requires pharmaceutical manufacturers to issue rebates to Medicaid for covered outpatient drugs. When they offer prescription drug  benefits, Medicaid programs must cover nearly all drugs, potentially reducing Medicaid’s leverage to negotiate discounts. Policymakers created…

Pharma Marketing 101

Drug policy 101: Pharmaceutical marketing tactics

  • February 4, 2020

Pharmaceutical marketing aims to shape both patient and clinician perceptions about a drug’s benefit and can significantly impact patient and clinician decisions that then affect outcomes, in addition to draining government and health care system resources. This paper describes the…

When the best prescription is deprescribing

  • January 29, 2020

Several years ago, an elderly patient — let’s call her Eve — came to Kaiser Permanente because she was dazed and feeling “out of it” on a regular basis. Her family chalked it up to old age and eventually contemplated…

Polly Webster

The promise — and challenges — of gene therapy

  • January 6, 2020

What good is a life-saving, ground-breaking treatment that patients and the health care system cannot access or afford? This question was front of mind for me during last fall’s Brocher Foundation meeting about cell and gene therapies: cutting-edge therapies that…

Rena Conti

Determining drug value: Let’s start with the evidence

  • October 24, 2019

Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…

Drug policy 101: Breaking down different types of drug products

  • October 22, 2019

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions. This paper…

Drug policy 101: The state of the pharmaceutical evidence base

  • September 26, 2019

Having sound evidence about a drug’s safety and effectiveness is critical to understanding its benefits and value. In recent years, shifts in the pharmaceutical evidence base have created challenges for evaluating drugs after they come to market. This brief describes…


How to save the patent system in 3 easy steps

  • May 30, 2019

Patents are in the news as Congress considers legislation to address patent abuses and anticompetitive behavior by the pharmaceutical industry. If you’re tuning into these issues for the first time (or even the second or third) you’ll notice that there…